Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181308 · ClinicalTrials.gov registry record · Phase 1
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
A Phase 1 study, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT03181308 is a Phase 1 study that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT03181308, a Phase 1 study, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or PD-1/PD-L1 checkpoint inhibition, as a single agent or with chemotherapy.
Interventions
- DRUG OPDIVO
- DRUG Carotuximab (TRC105)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2017-11-09 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03181308
The ClinicalTrials.gov registry entry for NCT03181308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OPDIVO is the first listed.
NCT03181308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03181308 about?
NCT03181308 is a clinical study titled "Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC". This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or PD-1/PD-L1 checkpoint inhibition, as a single agent or with chemotherapy...
What is the current status of trial NCT03181308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2017-11-09. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT03181308?
The interventions under investigation include: OPDIVO (DRUG), Carotuximab (TRC105) (DRUG).
Who is sponsoring clinical trial NCT03181308?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.